Mainz Biomed NV (MYNZ)
(Delayed Data from NSDQ)
$1.62 USD
-0.11 (-6.36%)
Updated Oct 6, 2025 04:00 PM ET
After-Market: $1.63 +0.01 (0.62%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MYNZ 1.62 -0.11(-6.36%)
Will MYNZ be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for MYNZ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MYNZ
Monte Rosa Therapeutics (GLUE) Q4 Earnings and Revenues Top Estimates
Immunome, Inc. (IMNM) Reports Q4 Loss, Misses Revenue Estimates
MYNZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Anika Therapeutics (ANIK) Reports Q4 Loss, Tops Revenue Estimates
Other News for MYNZ
20 Day Moving Average Support appears for MYNZ after 5.49% move
MYNZ Crossed Above 20 Day Moving Average on October 2
Mainz Biomed Enters $10 Million Equity Distribution Agreement with Maxim Group
Is MYNZ ready to move higher? Stochastic Buy Signal shows up after gaining 4.7%
Is MYNZ likely to continue lower? Lower Bollinger Band Walk shows up after rising 2.05%